Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Blood - Tập 130 Số 21 - Trang 2295-2306 - 2017
Kevin A. Hay1,2, Laïla‐Aïcha Hanafi1, Daniel Li3, Juliane Gust4, W. Conrad Liles5, Mark M. Wurfel5, José A. López6,5, Junmei Chen6, Werner Müller‐Esterl6, Susanna Harju-Baker5, Sindhu Cherian7, Xueyan Chen7, Stanley R. Riddell1,5, David G. Maloney1,5, Cameron J. Turtle1,5
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
2Department of Medicine, University of British Columbia, Vancouver, BC, Canada
3Juno Therapeutics, Seattle, WA
4Seattle Children's Hospital, Seattle, WA
5Department of Medicine, University of Washington, Seattle, WA
6Bloodworks Northwest, Seattle, WA; and
7Department of Laboratory Medicine, University of Washington, Seattle, WA

Tóm tắt

Key Points Characterization of the kinetics and risk factors for severe CRS after CD19 CAR T cells will facilitate preemptive therapy and management. Severe CRS is characterized by endothelial activation.

Từ khóa


Tài liệu tham khảo

Turtle, 2016, Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells, Sci Transl Med, 8, 355ra116, 10.1126/scitranslmed.aaf8621

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309

Turtle, 2016, CD19 CAR-T cells are highly effective in ibrutinib-refractory chronic lymphocytic leukemia [abstract], Blood, 128, 10.1182/blood.V128.22.56.56

Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol, 33, 540, 10.1200/JCO.2014.56.2025

Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, 7, 303ra139, 10.1126/scitranslmed.aac5415

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226

Locke, 2017, Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma, Mol Ther, 25, 285, 10.1016/j.ymthe.2016.10.020

Hay, 2017, Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies, Drugs, 77, 237, 10.1007/s40265-017-0690-8

Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208

Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med, 5, 177ra38, 10.1126/scitranslmed.3005930

Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540

Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849

Fitzgerald, 2017, Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia, Crit Care Med, 45, e124, 10.1097/CCM.0000000000002053

Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751

Maude, 2014, Managing cytokine release syndrome associated with novel T cell-engaging therapies, Cancer J, 20, 119, 10.1097/PPO.0000000000000035

Wang, 2011, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, 118, 1255, 10.1182/blood-2011-02-337360

Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 188, 10.1182/blood-2014-05-552729

Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Cancer Discov, 6, 664, 10.1158/2159-8290.CD-16-0040

Valentijn, 2011, Functional architecture of Weibel-Palade bodies, Blood, 117, 5033, 10.1182/blood-2010-09-267492

Fiedler, 2004, The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies, Blood, 103, 4150, 10.1182/blood-2003-10-3685

Metcalf, 2008, Formation and function of Weibel-Palade bodies, J Cell Sci, 121, 19, 10.1242/jcs.03494

Mikacenic, 2015, Biomarkers of endothelial activation are associated with poor outcome in critical illness, PLoS One, 10, e0141251, 10.1371/journal.pone.0141251

Page, 2013, Biomarkers of endothelial activation/dysfunction in infectious diseases, Virulence, 4, 507, 10.4161/viru.24530

Page, 2013, Dysregulation of angiopoietin 1 and 2 in Escherichia coli O157:H7 infection and the hemolytic-uremic syndrome, J Infect Dis, 208, 929, 10.1093/infdis/jit268

Page, 2011, Systemic dysregulation of angiopoietin-1/2 in streptococcal toxic shock syndrome, Clin Infect Dis, 52, e157, 10.1093/cid/cir125

Ricciuto, 2011, Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis, Crit Care Med, 39, 702, 10.1097/CCM.0b013e318206d285

Lovegrove, 2009, Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children, PLoS One, 4, e4912, 10.1371/journal.pone.0004912

Darwish, 2013, Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction, Virulence, 4, 572, 10.4161/viru.25740

Ali, 2016, T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma, Blood, 128, 1688, 10.1182/blood-2016-04-711903